1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Pneumococcal Vaccines Market
2.3. Global Pneumococcal Vaccines Market, By Vaccine, 2025 (US$ Million)
2.4. Global Pneumococcal Vaccines Market, By Product, 2025 (US$ Million)
2.5. Global Pneumococcal Vaccines Market, By Geography, 2025 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2025
3. Pneumococcal Vaccines Market: Competitive Analysis
3.1. Market Positioning of Key Pneumococcal Vaccines Market Vendors
3.2. Strategies Adopted by Pneumococcal Vaccines Market Vendors
4. Pneumococcal Vaccines Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Pneumococcal Vaccines Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape
5. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Pneumococcal Conjugate Vaccine
5.3.2. Pneumococcal Polysaccharide Vaccine
6. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2025 Versus 2034
6.3. Market Segmentation
6.3.1. 10-valent PCV
6.3.2. 13-valent PCV
6.3.3. 23-valent PPSV
6.3.4. Pipeline Analysis
6.3.4.1. Phase III Analysis
6.3.4.1.1. 15-valent PCV
6.3.4.1.2. 20-valent PCV
6.3.4.2. Tabular Representation of Phase I and Phase II Vaccines
7. North America Pneumococcal Vaccines Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
7.3. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
7.4. Pneumococcal Vaccines Market: By Region, 2024-2034, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
7.4.1.1.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
7.4.1.2.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
7.4.1.3.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
8. UK and European Union Pneumococcal Vaccines Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
8.3. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
8.4. Pneumococcal Vaccines Market: By Region, 2024-2034, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
8.4.1.1.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
8.4.1.2.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
8.4.1.3.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
8.4.1.4.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
8.4.1.5. France
8.4.1.5.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
8.4.1.5.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
8.4.1.6.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
9. Asia Pacific Pneumococcal Vaccines Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
9.3. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
9.4. Pneumococcal Vaccines Market: By Region, 2024-2034, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
9.4.1.1.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
9.4.1.2.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
9.4.1.3. India
9.4.1.3.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
9.4.1.3.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
9.4.1.4.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
9.4.1.5.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
9.4.1.6.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
10. Latin America Pneumococcal Vaccines Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
10.3. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
10.4. Pneumococcal Vaccines Market: By Region, 2024-2034, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
10.4.1.1.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
10.4.1.2.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
10.4.1.3.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
11. Middle East and Africa Pneumococcal Vaccines Market, 2024-2034, USD (Million)
11.1. Market Overview
11.2. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
11.3. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
11.4. Pneumococcal Vaccines Market: By Region, 2024-2034, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
11.4.1.1.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
11.4.1.2.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Pneumococcal Vaccines Market: By Vaccine, 2024-2034, USD (Million)
11.4.1.3.2. Pneumococcal Vaccines Market: By Product, 2024-2034, USD (Million)
12. Company Profile
12.1. Pfizer, Inc. (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
12.2. GlaxoSmithKline PLC
12.3. Merck & Co., Inc.
